The global spread of drug-resistant influenza

Resistance to oseltamivir, the most widely used influenza antiviral drug, spread to fixation in seasonal influenza A(H1N1) between 2006 and 2009. This sudden rise in resistance seemed puzzling given the low overall level of the oseltamivir usage and the lack of a correlation between local rates of resistance and oseltamivir usage. We used a stochastic simulation model and deterministic approximations to examine how such events can occur, and in particular to determine how the rate of fixation of the resistant strain depends both on its fitness in untreated hosts as well as the frequency of antiviral treatment. We found that, for the levels of antiviral usage in the population, the resistant strain will eventually spread to fixation, if it is not attenuated in transmissibility relative to the drug-sensitive strain, but not at the speed observed in seasonal H1N1. The extreme speed with which the resistance spread in seasonal H1N1 suggests that the resistant strain had a transmission advantage in untreated hosts, and this could have arisen from genetic hitchhiking, or from the mutations responsible for resistance and compensation. Importantly, our model also shows that resistant virus will fail to spread if it is even slightly less transmissible than its sensitive counterpart—a finding of relevance given that resistant pandemic influenza (H1N1) 2009 may currently suffer from a small, but nonetheless experimentally perceptible reduction in transmissibility.

[1]  Cecile Viboud,et al.  Phylogenetic Analysis Reveals the Global Migration of Seasonal Influenza A Viruses , 2007, PLoS pathogens.

[2]  F. Hayden,et al.  Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. , 2001, The Journal of infectious diseases.

[3]  R. Saito,et al.  Genetic Makeup of Amantadine-Resistant and Oseltamivir-Resistant Human Influenza A/H1N1 Viruses , 2010, Journal of Clinical Microbiology.

[4]  V. Caron,et al.  United states. , 2018, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[5]  Jessica B. Graham The Global Spread of Drug-Resistant Influenza , 2011 .

[6]  A. Monto,et al.  Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets. , 2002, Antiviral research.

[7]  C. Viboud,et al.  Explorer The genomic and epidemiological dynamics of human influenza A virus , 2016 .

[8]  Mark A. Miller,et al.  The genesis and spread of reassortment human influenza A/H3N2 viruses conferring adamantane resistance. , 2007, Molecular biology and evolution.

[9]  G. Kobinger,et al.  Oseltamivir-Resistant Pandemic A/H1N1 Virus Is as Virulent as Its Wild-Type Counterpart in Mice and Ferrets , 2010, PLoS pathogens.

[10]  A. Nizam,et al.  Containing Pandemic Influenza at the Source , 2005, Science.

[11]  W. Barclay,et al.  Pandemic H1N1 2009 influenza virus with the H275Y oseltamivir resistance neuraminidase mutation shows a small compromise in enzyme activity and viral fitness , 2010, The Journal of antimicrobial chemotherapy.

[12]  Guy Boivin,et al.  Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors. , 2011, The Journal of infectious diseases.

[13]  Pia Abel zur Wiesch,et al.  Population biological principles of drug-resistance evolution in infectious diseases. , 2011, The Lancet. Infectious diseases.

[14]  H. Klenk,et al.  Functional balance between haemagglutinin and neuraminidase in influenza virus infections , 2002, Reviews in medical virology.

[15]  M. Elizabeth Halloran,et al.  Containing Pandemic Influenza at the Source , 2005, Science.

[16]  S. van der Werf,et al.  Enzymatic Properties of the Neuraminidase of Seasonal H1N1 Influenza Viruses Provide Insights for the Emergence of Natural Resistance to Oseltamivir , 2008, PLoS pathogens.

[17]  Makoto Ujike,et al.  A two-year survey of the oseltamivir-resistant influenza A(H1N1) virus in Yamagata, Japan and the clinical effectiveness of oseltamivir and zanamivir , 2010, Virology Journal.

[18]  A. Nicoll,et al.  Use of oseltamivir in 12 European countries between 2002 and 2007--lack of association with the appearance of oseltamivir-resistant influenza A(H1N1) viruses. , 2009, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[19]  E. Holmes,et al.  Homologous Recombination Is Very Rare or Absent in Human Influenza A Virus , 2008, Journal of Virology.

[20]  Nicole M. Bouvier,et al.  Oseltamivir-Resistant Influenza A Viruses Are Transmitted Efficiently among Guinea Pigs by Direct Contact but Not by Aerosol , 2008, Journal of Virology.

[21]  G. Boivin,et al.  A Reverse Genetics Study of Resistance to Neuraminidase Inhibitors in An Influenza A/H1N1 Virus , 2003, Antiviral therapy.

[22]  A. Monto,et al.  Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. , 2004, The Journal of infectious diseases.

[23]  J. van de Kassteele,et al.  Oseltamivir-Resistant Influenza Virus A (H1N1), Europe, 2007–08 Season , 2009, Emerging infectious diseases.

[24]  M. Halloran,et al.  Antiviral effects on influenza viral transmission and pathogenicity: observations from household-based trials. , 2006, American journal of epidemiology.

[25]  J. Oxford,et al.  Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo. , 2002, Antiviral research.

[26]  G. Boivin,et al.  Effect of the neuraminidase mutation H274Y conferring resistance to oseltamivir on the replicative capacity and virulence of old and recent human influenza A(H1N1) viruses. , 2010, The Journal of infectious diseases.

[27]  A. Lapedes,et al.  Mapping the Antigenic and Genetic Evolution of Influenza Virus , 2004, Science.

[28]  A. Moscona,et al.  Global transmission of oseltamivir-resistant influenza. , 2009, The New England journal of medicine.

[29]  Jonathan Dushoff,et al.  Hemagglutinin sequence clusters and the antigenic evolution of influenza A virus , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[30]  G. Kochs,et al.  Oseltamivir-Resistant Variants of the 2009 Pandemic H1N1 Influenza A Virus Are Not Attenuated in the Guinea Pig and Ferret Transmission Models , 2010, Journal of Virology.

[31]  Ryo Takano,et al.  Characterization of Oseltamivir-Resistant 2009 H1N1 Pandemic Influenza A Viruses , 2010, PLoS pathogens.

[32]  M. Pascual,et al.  Global Migration Dynamics Underlie Evolution and Persistence of Human Influenza A (H3N2) , 2010, PLoS pathogens.

[33]  H. Niman Emergence and Fixing of Antiviral Resistance in Influenza A Via Recombination and Hitch Hiking , 2009 .

[34]  P. Ward,et al.  Oral oseltamivir treatment of influenza in children , 2001, The Pediatric infectious disease journal.

[35]  D. Cummings,et al.  Strategies for containing an emerging influenza pandemic in Southeast Asia , 2005, Nature.

[36]  M. Halloran,et al.  The Global Transmission and Control of Influenza , 2011, PloS one.

[37]  R. Webster,et al.  Oseltamivir–Resistant Pandemic H1N1/2009 Influenza Virus Possesses Lower Transmissibility and Fitness in Ferrets , 2010, PLoS pathogens.

[38]  R. Saito,et al.  Emergence of H274Y oseltamivir-resistant A(H1N1) influenza viruses in Japan during the 2008-2009 season. , 2010, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[39]  David Baltimore,et al.  Permissive Secondary Mutations Enable the Evolution of Influenza Oseltamivir Resistance , 2010, Science.

[40]  J. Oxford,et al.  The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. , 2002, Antiviral research.

[41]  P. Collins,et al.  Structural basis for oseltamivir resistance of influenza viruses. , 2009, Vaccine.

[42]  R. Epstein,et al.  Oseltamivir Prescribing in Pharmacy-Benefits Database, United States, 2004–2005 , 2008, Emerging infectious diseases.